Patients with ALL have Ikaros mutations with characteristic resistance to treatment (Marke et al., 2016), high relapse rate (Kuiper et al., 2010; Berry et al., 2020), and poor prognosis (Mullighan et al., 2009; Aref et al., 2020). Here, IKZF1 is linked to acute lymphoblastic leukemia.